Ad is loading...
MENU

OBIO Stock Tickeron detected bullish Stock Pattern: Triangle Symmetrical Bottom OBIO on October 14, 2024, netting in a 6.83% gain over 7 days

A.I.dvisor
at Tickeron.com
Loading...
+6.83% Gain from a Successful pattern Triangle Symmetrical Bottom
OBIO - Orchestra BioMed Holdings
Tickeron
Ticker: OBIO
Company: Orchestra BioMed Holdings
Gain: +6.83%
Confirmed: 10/14/24
Succeeded: 10/15/24
Total length: 7 days
On October 08, 2024, A.I.dvisor detected a Triangle Symmetrical Bottom Pattern (Bullish) for Orchestra BioMed Holdings (OBIO, $4.98). On October 14, 2024, A.I.dvisor confirmed the Bullish pattern, setting a target price of $5.67. 1 day later, on October 15, 2024, OBIO reached the target price resulting in a for traders who took a long position in the stock.

OBIO in upward trend: 10-day moving average moved above 50-day moving average on October 25, 2024

The 10-day moving average for OBIO crossed bullishly above the 50-day moving average on October 25, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

OBIO moved above its 50-day moving average on November 21, 2024 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OBIO advanced for three days, in of 170 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 123 cases where OBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 19, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on OBIO as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for OBIO turned negative on November 18, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

OBIO broke above its upper Bollinger Band on October 22, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.452) is normal, around the industry mean (13.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.241). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.798). OBIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (74.074) is also within normal values, averaging (221.024).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
OBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
150 Union Square Drive,
Phone
+1 215 862-5797
Employees
56
Web
https://www.orchestrabiomed.com